{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:05:47Z","timestamp":1767773147404,"version":"build-2238731810"},"update-to":[{"DOI":"10.1080\/13696998.2022.2048573","type":"addendum","label":"Addendum","source":"publisher","updated":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000}}],"reference-count":51,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/13696998.2022.2077549","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T07:52:20Z","timestamp":1654501940000},"page":"703-711","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States"],"prefix":"10.1080","volume":"25","author":[{"given":"Malin","family":"Berling","sequence":"first","affiliation":[{"name":"Parexel International, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6552-9093","authenticated-orcid":false,"given":"Mohammad A.","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nebibe","family":"Varol","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Uxbridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dale","sequence":"additional","affiliation":[{"name":"Parexel International, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9878-7299","authenticated-orcid":false,"given":"Eleonora","family":"Testa","sequence":"additional","affiliation":[{"name":"Parexel International, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7023-7685","authenticated-orcid":false,"given":"Johan","family":"Klint","sequence":"additional","affiliation":[{"name":"Parexel International, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8834-1296","authenticated-orcid":false,"given":"Adam","family":"Lee","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Uxbridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0539-9156","authenticated-orcid":false,"given":"Solomon J.","family":"Lubinga","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Penrod","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_4_3_1","unstructured":"American Cancer Society. Lung cancer survival rates; 2021. [cited 2021 June 15] Available from: https:\/\/www.cancer.org\/cancer\/lung-cancer\/detection-diagnosis-staging\/survival-rates.html."},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2009.03.014"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-079X.2003.00032.x"},{"key":"e_1_3_4_6_1","unstructured":"Noone A Howlader N Krapcho M et\u00a0al. SEER Cancer Statistics Review (CSR) 1975-2015; 2018. [cited 2021 October 26] Available from: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2015\/."},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01605"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0412"},{"key":"e_1_3_4_9_1","unstructured":"OPDIVO (nivolumab) [prescribing information]; 2021. Bristol Myers Squibb: Princeton NJ."},{"key":"e_1_3_4_10_1","unstructured":"YERVOY (ipilimumab) [prescribing information]; 2020. Bristol Myers Squibb: Princeton NJ."},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.547"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4_suppl.11"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.LBA4001"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9500"},{"key":"e_1_3_4_21_1","unstructured":"US Food & Drug Administration FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression \u22651%). 2020."},{"key":"e_1_3_4_22_1","unstructured":"Latimer NR. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data; 2011. [updated 2013 March; cited 2021 July 8]. Available from: https:\/\/www.sheffield.ac.uk\/sites\/default\/files\/2022-02\/TSD14-Survival-analysis.updated-March-2013.v2.pdf."},{"key":"e_1_3_4_23_1","unstructured":"National Institute for Health and Care Excellence. NICE technology appraisal guidance [TA531]: pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer; 2018. [updated 2021 February 13; cited 2021 June 15]; Available from: https:\/\/www.nice.org.uk\/guidance\/ta531\/resources\/pembrolizumab-for-untreated-pdl1positive-metastatic-nonsmallcell-lung-cancer-pdf-82606895901637."},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2021.88726"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0527-z"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1521416"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1571297"},{"key":"e_1_3_4_28_1","volume-title":"Cost effectiveness in health and medicine","author":"Neumann PJ","year":"2017","unstructured":"Neumann PJ, Ganiats TG, Russell LB, et\u00a0al. Cost effectiveness in health and medicine. Second ed. 2017. Oxford; New York: Oxford University Press: Oxford Scholarship Online."},{"key":"e_1_3_4_29_1","unstructured":"Rutherford MJ Lambert PC Sweeting MJ et\u00a0al. NICE DSU technical support document 21: flexible methods for survival analysis. Report by the Decision Support Unit; 2020. [cited 2021 July 8]. Available from: https:\/\/nicedsu.sites.sheffield.ac.uk\/tsds\/flexible-methods-for-survival-analysis-tsd."},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.486"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200503000-00003"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.3727\/096504019X15707883083132"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.11952"},{"key":"e_1_3_4_34_1","unstructured":"US Bureau of Labor Statistics. Consumer price index; 2021. [updated 2021 March 17; cited 2021 June 15]. Available from: https:\/\/www.bls.gov\/cpi\/data.htm."},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216315596505"},{"key":"e_1_3_4_36_1","unstructured":"National Institute for Health and Care Excellence. Nivolumab for previously treated squamous non-small-cell lung cancer [TA483]; 2017. [updated 2018 May 28; cited 2021 May 15]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta483."},{"key":"e_1_3_4_37_1","unstructured":"National Institute for Health and Care Excellence. Nivolumab for previously treated non-squamous non-small-cell lung cancer [TA484]; 2017. [updated 2018 May 28; cited 2021 May 15]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta484."},{"key":"e_1_3_4_38_1","unstructured":"National Institute for Health and Care Excellence. NICE technology appraisal guidance [TA655]: nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy; 2020. [updated 2021 June 15; cited 2021 June 15]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta655."},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.14.138206"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.14.1637"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-2-90"},{"key":"e_1_3_4_42_1","doi-asserted-by":"crossref","unstructured":"Becker G Murphy K Philipson T. The value of life near its end and terminal care. National Bureau of Economic Research working paper No. 13333. August; 2007. [cited 2015 June 15]. Available from: https:\/\/www.nber.org\/system\/files\/working_papers\/w13333\/w13333.pdf.","DOI":"10.3386\/w13333"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8787"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0112"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01649"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2016.1151432"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3708"},{"key":"e_1_3_4_48_1","unstructured":"National Cancer Institute. Cancer Query System: SEER survival statistics; 2021. [cited 2021 June 15]. Available from: https:\/\/seer.cancer.gov\/canques\/survival.html."},{"key":"e_1_3_4_49_1","unstructured":"Bristol Meyers Squibb. Four-year data from phase 3 CheckMate-227 trial show durable long-term survival with Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with non-small cell lung cancer with PD-L1 expression \u22651%. 2021."},{"key":"e_1_3_4_50_1","unstructured":"Federal Reserve Economic Data. Consumer Price Index for All Urban Consumers: Medical Care in U.S. City Average; 2022. [cited 2022 February 28]. Available from: https:\/\/fred.stlouisfed.org\/series\/CPIMEDSL."},{"key":"e_1_3_4_51_1","unstructured":"Kluwer W. Medi-Span PriceRx database; 2021. [cited 2021 February 13]. Available from: https:\/\/pricerx.medispan.com."},{"key":"e_1_3_4_52_1","unstructured":"Centers for Medicare and Medicaid Services 2019 CMS clinical laboratory fee schedule; 2019."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2022.2077549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T07:28:17Z","timestamp":1729150097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2022.2077549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/13696998.2022.2077549"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2022.2077549","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}